25 Feb 2026 AYUR.CN jumps 100% to C$0.01 on CNQ: Watch earnings catalyst

AYUR.CN stock surged 100.00% intraday to C$0.01 on CNQ during market hours on 25 Feb 2026. The move followed low liquidity and a tight float that pushed volume to 102,450 shares versus an average of 141,522. Investors should note the scheduled earnings announcement on 04 Mar 2026 as a near-term catalyst that can widen price swings.

Intraday move and near-term catalyst for AYUR.CN stock

The key fact is the intraday jump of 100.00% to C$0.01 on CNQ. This reflects low absolute price and a small market cap of C$1,947,039, which amplifies small flows into large percentage moves. Volume rose to 102,450 shares versus an average of 141,522, showing increased interest but still limited liquidity. The company reports earnings on 04 Mar 2026, a likely trigger for follow-through moves in either direction.

Financial snapshot and valuation metrics for AYUR.CN stock

Ayurcann Holdings Corp. shows trailing EPS of -0.03 and a negative P/E of -0.33. Revenue per share TTM is 0.16, while book value per share is negative at -0.02. Price averages are depressed: 50-day C$0.02 and 200-day C$0.03. Market-cap and per-share metrics imply speculative status, with price-to-sales at 0.06 and price-to-free-cash-flow near 3.10.

Technicals, volume and sector context for AYUR.CN stock

Momentum indicators show mixed signals: RSI 50.94, CCI 214.67, and ROC 100.00%. ADX at 34.79 suggests a strong intraday trend. Bollinger bands span C$0.00–C$0.01, reflecting low absolute volatility. Healthcare sector performance is negative YTD at -3.07%, which adds headwinds for AYUR.CN stock despite pockets of recovery in small cannabis services firms.

Meyka AI grade and model forecast for AYUR.CN stock

Meyka AI rates AYUR.CN with a score out of 100: 73.80 | Grade B+ | Suggestion BUY. This grade factors in S&P 500 comparison, sector and industry peers, financial growth, key metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects monthly C$0.01, quarterly C$0.02, and yearly C$0.016. Compared with the current price of C$0.01, the one-year implied upside is 63.17%. Forecasts are model-based projections and not guarantees.

Risk profile, liquidity and downside scenarios for AYUR.CN stock

Primary risks include low liquidity, negative EPS, and a tiny market cap of C$1,947,039. Shares outstanding are 194,703,863, which can dilute gains if capital raises occur. Downside is meaningful: a three-year forecast of C$0.00578 implies -42.24% from the current price. Investors should expect wide bid-ask spreads and high intraday volatility.

Price targets, trade setups and AYUR.CN stock opportunity

Short-term traders may use a scalp target of C$0.02 and a stop near C$0.005 given the day range. A conservative 12-month fair-value scenario sits at C$0.016, based on Meyka forecasts and sector comparisons. Bull case price target of C$0.05 aligns with the 52-week high of C$0.045, while the conservative bear case sits near C$0.005. Position sizing and strict risk controls are essential.

Final Thoughts

AYUR.CN stock moved sharply higher today, rising 100.00% to C$0.01 on CNQ during market hours. The surge reflects low absolute price and thin liquidity rather than a change in fundamentals. Near-term focus is the earnings release on 04 Mar 2026, which could confirm revenue progress or highlight margin pressures. Meyka AI’s forecast model projects a one-year target near C$0.016, implying 63.17% upside from the current price, while a three-year projection implies a downside near -42.24%. Meyka AI grades AYUR.CN B+ (73.80) and flags both opportunity and risk. Traders should treat this as a speculative, high-volatility instrument and size positions accordingly. For live filings and company disclosures consult the company website and verified filings before trading. Remember, forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.